Skip to main content

Advertisement

SpringerLink
Log in

Prognostic significance of Ki-67 antigen expression in extranodal natural killer/T-cell lymphoma, nasal type

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Extranodal natural killer (NK)/T-cell lymphoma, nasal-type (ENKTL) is a clinically heterogeneous disease with poor prognosis and requires risk stratification in affected patients. Recent studies have shown that Ki-67 may serve as a prognostic marker in certain types of lymphoma. We analyzed Ki-67 expression and its correlation with prognosis in 182 patients with ENKTL from January 2002 to June 2013. The patients were classified into two groups through a median value: low (<60 %) versus high Ki-67 (≥60 %). High Ki-67 expression was more common in patients with B symptoms (p = 0.02), bulky disease (p = 0.001), and extraupper aerodigestive tract NK/T-cell lymphoma (p = 0.001). High Ki-67 expression was significantly associated with poor overall survival (p < 0.0001) and progression-free survival (p < 0.0001). For patients with low-risk IPI or KPI, Ki-67 at diagnosis could contribute to distinguish patients with favorable outcomes from those with poor outcomes. The results of multivariate analysis showed that the high Ki-67 expression is an independent prognostic factor for overall survival and progression-free survival. (OS, p = 0.001; PFS, p = 0.003). Our data showed that Ki-67 is an effective prognostic indicator of survival in ENKTL patients. This prognostic index may be helpful in identifying high-risk patients with ENKTL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24(4):612–8. doi:10.1200/JCO.2005.04.1384.

    Article  PubMed  Google Scholar 

  2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30. doi:10.1200/JCO.2008.16.4558.

    Article  PubMed  Google Scholar 

  3. Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83–7.

    PubMed  CAS  Google Scholar 

  4. Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138(3):429–34. doi:10.1309/AJCP7YLTQPUSDQ5C.

    Article  PubMed  Google Scholar 

  5. Kim TM, Park YH, Lee SY, Kim JH, Kim DW, Im SA, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood. 2005;106(12):3785–90. doi:10.1182/blood-2005-05-2056.

    Article  PubMed  CAS  Google Scholar 

  6. Aviles A, Diaz NR, Neri N, Cleto S, Talavera A. Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol. 2000;22(4):215–20. doi:10.1046/j.1365-2257.2000.00307.x.

    Article  PubMed  CAS  Google Scholar 

  7. Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002;54(1):182–90. doi:10.1016/S0360-3016(02)02916-4

    Article  PubMed  Google Scholar 

  8. Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103(1):216–21. doi:10.1182/blood-2003-05-1401.

    Article  PubMed  CAS  Google Scholar 

  9. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113(17):3931–7. doi:10.1182/blood-2008-10-185256.

    Article  PubMed  CAS  Google Scholar 

  10. Velders GA, Kluin-Nelemans JC, De Boer CJ, Hermans J, Noordijk EM, Schuuring E, et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol. 1996;14(4):1269–74.

    PubMed  CAS  Google Scholar 

  11. Pastuszewski W, Dziegiel P, Krecicki T, Podhorska-Okolow M, Ciesielska U, Gorzynska E, et al. Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer. Anticancer Res. 2007;27(1A):335–42.

    PubMed  CAS  Google Scholar 

  12. Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res. 2000;257(2):231–7. doi:10.1006/excr.2000.4888.

    Article  PubMed  CAS  Google Scholar 

  13. Llanos M, Alvarez-Arguelles H, Aleman R, Oramas J, Diaz-Flores L, Batista N. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol. 2001;18(1):15–22. doi:10.1385/MO:18:1:15.

    Article  PubMed  CAS  Google Scholar 

  14. He X, Chen Z, Fu T, Jin X, Yu T, Liang Y, et al. Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer. 2014;14:153. doi:10.1186/1471-2407-14-153.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kim SJ, Kim BS, Choi CW, Choi J, Kim I, Lee YH, et al. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol. 2007;18(8):1382–7. doi:10.1093/annonc/mdm183.

    Article  PubMed  CAS  Google Scholar 

  16. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.

    Google Scholar 

  17. Kim TM, Heo DS. Extranodal NK/T-cell lymphoma, nasal type: new staging system and treatment strategies. Cancer Sci. 2009;100(12):2242–8. doi:10.1111/j.1349-7006.2009.01319.x.

    Article  PubMed  CAS  Google Scholar 

  18. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31(11):1860–1.

    PubMed  CAS  Google Scholar 

  19. Shipp MA, Harrington DP, Anderson JR. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987–94. doi:10.1056/NEJM199309303291402.

  20. Wang L, Wang Zh, Chen Xq, Li Yj, Wang Kf, Xia Yf et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T‐cell lymphoma. Cancer. 2013;119(2):348–55.

  21. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.

    PubMed  CAS  Google Scholar 

  22. Grillo-Lopez AJ, Cheson BD, Horning SJ, Peterson BA, Carter WD, Varns CL, et al. Response criteria for NHL: importance of ‘normal’ lymph node size and correlations with response rates. Ann Oncol. 2000;11(4):399–408.

    Article  PubMed  CAS  Google Scholar 

  23. Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, et al. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. 1993;123(3):513–22.

    Article  PubMed  CAS  Google Scholar 

  24. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311–22. doi:10.1002/(SICI)1097-4652(200003)182:3<311:AID-JCP1>3.0.CO;2-9.

    Article  PubMed  CAS  Google Scholar 

  25. Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003;101(1):78–84. doi:10.1182/blood-2002-04-1286.

    Article  PubMed  CAS  Google Scholar 

  26. Jerkeman M, Anderson H, Dictor M, Kvaloy S, Akerman M, Cavallin-Stahl E. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study. Ann Hematol. 2004;83(7):414–9. doi:10.1007/s00277-004-0855-x.

    Article  PubMed  CAS  Google Scholar 

  27. Szczuraszek K, Mazur G, Jelen M, Dziegiel P, Surowiak P, Zabel M. Prognostic significance of Ki-67 antigen expression in non-Hodgkin’s lymphomas. Anticancer Res. 2008;28(2A):1113–8.

    PubMed  Google Scholar 

  28. Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2010;21(5):1032–40. doi:10.1093/annonc/mdp418.

    Article  PubMed  CAS  Google Scholar 

  29. Huang JJ, Zhu YJ, Xia Y, Zhao W, Lin TY, Jiang WQ, et al. A novel prognostic model for extranodal natural killer/T-cell lymphoma. Med Oncol. 2012;29(3):2183–90. doi:10.1007/s12032-011-0030-x.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. State Key Laboratory of Oncology in South China, Guangzhou, China

    Li Jiang, Pengfei Li, Hua Wang, Jun Liu, Xinke Zhang, Huijuan Qiu & Bei Zhang

  2. VIP Region, Sun Yat-Sen University Cancer Center, Guangzhou, China

    Li Jiang, Huijuan Qiu & Bei Zhang

  3. Department of Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

    Pengfei Li

  4. Department of Hematology Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

    Hua Wang

  5. Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China

    Jun Liu & Xinke Zhang

  6. Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China

    Bei Zhang

Authors
  1. Li Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pengfei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hua Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xinke Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Huijuan Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bei Zhang.

Additional information

Li Jiang, Pengfei Li and Hua Wang have contributed equally to this work and should be considered co-first authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, L., Li, P., Wang, H. et al. Prognostic significance of Ki-67 antigen expression in extranodal natural killer/T-cell lymphoma, nasal type. Med Oncol 31, 218 (2014). https://doi.org/10.1007/s12032-014-0218-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0218-y

Keywords

Search

Navigation